Does 22q11.2 Deletion Syndrome Cause Parkinson's?

Adults with 22q11.2 deletion syndrome (22q11.2DS) have a significantly higher risk of developing Parkinson’s disease compared to the general population ^[1]. While pediatric care often focuses on the heart, immune system, and early development, routine neurological care in adulthood is critical because of this connection ^[2].

Increased Risk and Early Onset

In the general population, Parkinson’s disease is typically a condition of older age. However, adults with 22q11.2DS face a higher risk of developing early-onset Parkinson’s disease, which generally begins in a person’s 30s or 40s ^[3][1]. It is important to note that while the relative risk is roughly 70 times higher than average, this does not mean every adult with the syndrome will develop Parkinson’s; it still only affects a minority of patients ^[1].

In addition to Parkinson’s disease, individuals with this syndrome also have a higher chance of experiencing other movement disorders, such as dystonia, which involves involuntary muscle contractions that cause repetitive or twisting movements ^[4].

Early Symptoms to Monitor

The clinical signs of Parkinson’s disease in someone with 22q11.2 deletion syndrome look very much like typical Parkinson’s disease ^[3]. Because the disease progresses gradually, catching it early is important. Early symptoms to watch for include:

• Tremors: Involuntary shaking, which often starts in a hand, finger, or limb while it is at rest.
• Rigidity: Muscle stiffness that can feel like a tight, persistent ache and may limit a person’s range of motion.
• Bradykinesia: Slowness of movement, which can make everyday tasks (like buttoning a shirt or walking) take longer and feel more difficult.
• Non-motor symptoms: While movement issues are the most obvious signs, Parkinson’s disease often begins with non-motor symptoms years before physical stiffness starts. These can include a loss of smell, chronic constipation, and REM sleep behavior disorder (physically acting out dreams) ^[5]. However, some autonomic nerve symptoms might be less prominent in 22q11.2DS than in standard Parkinson’s cases ^[6].

If Parkinson’s does develop, these symptoms generally respond well to standard Parkinson’s treatments (such as levodopa), just as they do in the general population ^[3][1].

A Unique Challenge: Psychiatric Medications

A significant complication in recognizing Parkinson’s disease in adults with 22q11.2DS involves the medications they might already be taking. Because individuals with the deletion have a higher risk of psychiatric conditions (such as schizophrenia or bipolar disorder), they are frequently prescribed antipsychotic medications ^[1].

A known side effect of many antipsychotics is drug-induced parkinsonism—symptoms like stiffness and tremors that perfectly mimic Parkinson’s disease. Because doctors may mistakenly assume that new movement problems are just a side effect of psychiatric medications, the actual diagnosis of Parkinson’s disease can be delayed by as much as 10 years ^[1].

Important Safety Warning: If you or your loved one experiences these physical symptoms, do not abruptly stop or change psychiatric medications on your own to see if the symptoms resolve. Doing so can cause a severe psychiatric relapse or withdrawal.

The Importance of Team-Based Care

Treating both conditions simultaneously can feel frightening to patients, as psychiatric medications often block dopamine while Parkinson’s treatments aim to increase it. This is why care must be managed collaboratively ^[2].

As individuals reach their late 20s and 30s, they should undergo routine neurological screenings ^[7]. It is vital to build a care team where a movement disorder specialist works directly with the patient’s psychiatrist. Together, they can find a medication balance that controls psychiatric symptoms without worsening movement issues.

To determine whether symptoms are medication side effects or true early-onset Parkinson’s, specialists can perform careful medication adjustments and use specialized brain imaging, such as a DaTscan, which helps doctors visualize dopamine activity in the brain to confirm dopaminergic loss ^[8]. Because 22q11.2DS is a genetic condition, genetic counseling is also recommended to discuss what this dual diagnosis might mean for family planning or other family members.